Keywords: Teva POharma, Restructuring plans, Xenon Pharma, XEN402, Copaxone

Teva fleshes out restructuring plan; licenses Xenon pain drug for $376 million

Article | 12 December 2012

Print This

Teva Pharmaceutical Industries (NYSE: TEVA's new chief executive Jeremy Levin has outlined the company's strategy for the next five years ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in